Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Bullboard Posts
Comment by Weebleon Dec 29, 2017 3:41pm
128 Views
Post# 27247854

RE:6 digit return

RE:6 digit returnI am pretty sure the managment are very competent at getting this through approval and getting this company to a buyout stage.  There has been progress and the presentations have been impressive.  With their (too cheap) shares and options, they are motivated and will be amply rewarded if this works out.   They will then pat each other on the back, and say what a great job they did and make (somebody) a lot of money. 

Sarcasm intended.   What about small shareholders?    Like others, I think the last financing was terrible.    I am not sure they care about or think about us at all.  I sent them a snotogram.....I don't expect a reply but at least they might know that there are some long suffering shareholders who aren't impressed.   We need to keep holding their feet to the fire and let them know that we expect better.

GLTA for 2018.
Bullboard Posts